Abbott gets rheumatoid arthritis test clearance
This article was originally published in The Gray Sheet
Executive Summary
Abbott plans to launch an Architect immunoassay in the U.S. by year-end to aid in the diagnosis of rheumatoid arthritis after receiving 510(k) clearance Oct. 20. The antibody cyclic-citrulinated peptide test is designed to run on Abbott's Architect i1000SR and i2000SR systems and is already available outside the U.S., according to the company. "Many patients with RA develop an immune response against proteins containing citrulline long before they present symptoms of the disease," the firm notes. "Studies show detecting the level of these antibodies earlier in the disease continuum, in conjunction with other clinical information, is critical to the early diagnosis of the disease.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.